<DOC>
	<DOCNO>NCT00696046</DOCNO>
	<brief_summary>Compared stemcell source cord blood ( CB ) easy safe procure , donor attrition , limitless supply , reduce viral transmission , less acute &amp; chronic GVHD , rich hematopoietic progenitor cell , immaturity T-cell-mediated immunity . CB delay neutrophil platelet engraftment , prolong immune reconstitution , uncertain graft-vs-tumor activity , cell dos single CB unit ( U ) limit factor large recipient Using intravenous route ( IV ) , close match patient ( pt ) donor CBU improve pt outcome transplant . Even though closely match CBU prefer , study suggest match may close needed marrow peripheral blood transplant If one uncommon tissue type , doctor may find closely match adult donor CBU may option , store ready use . GVHD complication allogeneic transplant . Studies found CBtransplant , few pt get GVHD marrow peripheral blood transplant . Pts study get GVHD CBtransplant tend get less severe case We hypothesize direct intrabone transplant CBcells could improve haematologic recovery due good stem cell homing , base follow observation : stem cell recirculate animal irradiate limb shielding ; limit fraction ( 10-15 % ) cell inject iv haematopoietic site , possibly large majority lose organ ; mousemodel , HSC directly inject ib repopulated marrow lethally irradiated mouse 10times efficiently HSC cell inject iv ; delay engraftment CB transplant possibly cause insufficient stem cell number ; indeed , child graft CB cell superior stem cell reservoir 1year posttransplant compare marrow transplant recipient Based data , set-up phase I-II study evaluate whether ib injection could safely perform whether procedure could ensure engraftment shorten time complete hematopoietic recovery adult high risk haematopoietic malignancy compare publish data . Neutrophil recovery &gt; 80 % day60 Platelets recovery &gt; 80 % days100 define success . 1° endpoint probability neutrophil platelet recovery ib CB transplant , 2° include incidence acute GVHD , relapse , overall survival</brief_summary>
	<brief_title>Intra Bone Marrow Injection Of Unrelated Cord Blood Cells</brief_title>
	<detailed_description>Study Design Phase I-II study . Neutrophil recovery &gt; 80 % day 60 Platelets recovery &gt; 80 % day 100 defined success . The limit 60 day neutrophil recovery chosen represent time rescue second transplant decide case failure engraft ; day 100 platelet recovery take corresponds first form report transplant European Blood Marrow Transplant Registry . HLA-A -B antigen identify low resolution DNA typing , whereas HLA-DRB1 type determine high resolution DNA type technique . HLA-A , HLA-B , HLA-DRB1 type use select closely match donor unit-recipient pair , preference give HLA-DRB1-matched unit</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>1 . Patients hematologic malignancy form hematologic disease include aplastic anemia 2 . Patients eligible enter study : A ) unrelated stem cell transplantation indicate ; b ) suitable unrelated HLAmatched donor identify clinically useful timeframe . 3 . Age 1670 4 . Serum creatinine &lt; 1.5 mg/dL Creatinine Clearance &gt; 50 ml/min 5 . Serum bilirubin &lt; 1.5 mg/dl , SGPT &lt; 3 x upper limit normal 6 . Negative serology HIV 7 . Central Venous access ( Central KT ) secure indwelling catheter . 8 . Life expectancy severely limited concomitant illness . 9 . Written sign inform consent 1 . Acute Myocardial Infarction ( AMI ) within last 12 month 2 . Positive pregnancy test 3 . Positive HIV serology 4 . Chronic renal insufficiency ( Serum creatinine &gt; 1.5 mg/dl creatinine cleareance &lt; =50 ml/min ) 5 . Patient another progressive malignant disease history malignancy within 2 year prior study entry . 6 . Severe psychiatric illness disorder compromise ability give truly informed consent participation study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>CORD BLOOD CELLS</keyword>
	<keyword>INTRA BONE MARROW INJECTION</keyword>
	<keyword>ENGRAFTMENT</keyword>
	<keyword>transplant</keyword>
</DOC>